505 related articles for article (PubMed ID: 22126264)
1. Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis.
Ferrándiz C; García A; Blasco AJ; Lázaro P
J Eur Acad Dermatol Venereol; 2012 Jun; 26(6):768-77. PubMed ID: 22126264
[TBL] [Abstract][Full Text] [Related]
2. [Efficiency of biologic agents in the treatment of moderate to severe psoriasis].
Blasco AJ; Lázaro P; Ferrándiz C; García-Díez A; Liso J
Actas Dermosifiliogr; 2009 Nov; 100(9):792-803. PubMed ID: 19889301
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of biologic therapies for plaque psoriasis.
Ahn CS; Gustafson CJ; Sandoval LF; Davis SA; Feldman SR
Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
[TBL] [Abstract][Full Text] [Related]
4. Cost-efficacy of biologic therapies for moderate to severe psoriasis from the perspective of the Taiwanese healthcare system.
Wang SH; Chi CC; Hu S
Int J Dermatol; 2014 Sep; 53(9):1151-6. PubMed ID: 24738910
[TBL] [Abstract][Full Text] [Related]
5. Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis.
Martin S; Feldman SR; Augustin M; Szapary P; Schenkel B
J Dermatolog Treat; 2011 Jun; 22(3):138-43. PubMed ID: 21254886
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of systemic therapies for moderate to severe psoriasis.
Sizto S; Bansback N; Feldman SR; Willian MK; Anis AH
Br J Dermatol; 2009 Jun; 160(6):1264-72. PubMed ID: 19120346
[TBL] [Abstract][Full Text] [Related]
7. Infliximab for the treatment of adults with psoriasis.
Loveman E; Turner D; Hartwell D; Cooper K; Clegg A
Health Technol Assess; 2009 Jun; 13 Suppl 1():55-60. PubMed ID: 19567215
[TBL] [Abstract][Full Text] [Related]
8. Biological treatments for moderate-to-severe psoriasis: indirect comparison.
Galván-Banqueri M; Marín Gil R; Santos Ramos B; Bautista Paloma FJ
J Clin Pharm Ther; 2013 Apr; 38(2):121-30. PubMed ID: 23442134
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials.
Reich K; Burden AD; Eaton JN; Hawkins NS
Br J Dermatol; 2012 Jan; 166(1):179-88. PubMed ID: 21910698
[TBL] [Abstract][Full Text] [Related]
10. Ustekinumab for the treatment of moderate to severe psoriasis.
Gospodarevskaya E; Picot J; Cooper K; Loveman E; Takeda A
Health Technol Assess; 2009 Oct; 13 Suppl 3():61-6. PubMed ID: 19846031
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period.
Nelson AA; Pearce DJ; Fleischer AB; Balkrishnan R; Feldman SR
J Am Acad Dermatol; 2008 Jan; 58(1):125-35. PubMed ID: 17996329
[TBL] [Abstract][Full Text] [Related]
12. Cost utility analysis based on a head-to-head Phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective.
Pan F; Brazier NC; Shear NH; Jivraj F; Schenkel B; Brown R
Value Health; 2011; 14(5):652-6. PubMed ID: 21839402
[TBL] [Abstract][Full Text] [Related]
13. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of TNF-alpha blockers for the treatment of chronic plaque psoriasis in the perspective of the Italian health-care system.
de Portu S; Del Giglio M; Altomare G; Arcangeli F; Berardesca E; Calzavara-Pinton P; Lotti T; Martini P; Peserico A; Simonacci M; Vena GA; Girolomoni G
Dermatol Ther; 2010; 23 Suppl 1():S7-13. PubMed ID: 20136921
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
[TBL] [Abstract][Full Text] [Related]
16. Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis.
Kirson NY; Rao S; Birnbaum HG; Kantor E; Wei RS; Cifaldi M
J Med Econ; 2013; 16(4):479-89. PubMed ID: 23339434
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response.
Signorovitch JE; Betts KA; Yan YS; LeReun C; Sundaram M; Wu EQ; Mulani P
Br J Dermatol; 2015 Feb; 172(2):504-12. PubMed ID: 25288183
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and cost-efficacy of biologic therapies for moderate to severe psoriasis: a meta-analysis and cost-efficacy analysis using the intention-to-treat principle.
Chi CC; Wang SH
Biomed Res Int; 2014; 2014():862851. PubMed ID: 24605338
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States.
Anis AH; Bansback N; Sizto S; Gupta SR; Willian MK; Feldman SR
J Dermatolog Treat; 2011 Apr; 22(2):65-74. PubMed ID: 20443663
[TBL] [Abstract][Full Text] [Related]
20. Cost-efficacy comparison of biological therapies for patients with moderate to severe psoriasis in Japan.
Igarashi A; Kuwabara H; Fahrbach K; Schenkel B
J Dermatolog Treat; 2013 Oct; 24(5):351-5. PubMed ID: 22632451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
